Drug Profile
Nowarta 110
Alternative Names: Nowarta110Latest Information Update: 05 Oct 2021
Price :
$50
*
At a glance
- Originator Nowarta Biopharma
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Warts
Most Recent Events
- 05 Oct 2021 Nowarta plans a phase III trial for Warts in 2021 (Nowarta pipeline, October 2021)
- 01 Dec 2015 Nowarta Biopharma completes a phase I/II trial in Warts (Recurrent) in USA (unspecified route) (NCT02338336)
- 13 Jan 2015 Clinical trials in Warts (unspecified route)